Cardiogeni（CGNI）株式概要臨床段階のバイオテクノロジー企業であるCardiogeni PLCは、心不全治療薬の開発を行っている。 詳細CGNI ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績4/6財務の健全性5/6配当金0/6報酬株価収益率（ 6.1 x） UK市場（ 15.8 x）を下回っています。今年は黒字化を達成 リスク分析意味のある時価総額がありません ( £7M )最新の財務報告は6か月以上前のものである すべてのリスクチェックを見るCGNI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW496,135 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG496,135 investors already sharing narrativesYour Fair ValueUK£Current PriceUK£0.0742.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6m8m2016201920222025202620282031Revenue UK£7.8mEarnings UK£1.1mAdvancedSet Fair ValueView all narrativesCardiogeni PLC 競合他社Arecor TherapeuticsSymbol: AIM:ARECMarket cap: UK£24.0mBioventixSymbol: AIM:BVXPMarket cap: UK£81.0mGenusSymbol: LSE:GNSMarket cap: UK£1.4bChina Regenerative Medicine InternationalSymbol: SEHK:8158Market cap: HK$82.1m価格と性能株価の高値、安値、推移の概要Cardiogeni過去の株価現在の株価UK£0.0752週高値UK£052週安値UK£0ベータ01ヶ月の変化0%3ヶ月変化0%1年変化-6.67%3年間の変化n/a5年間の変化n/aIPOからの変化-88.33%最新ニュースBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 17Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI).Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI) on March 16, 2026. In accordance with the terms of the proposed Transaction, Kira will provide up to $25 million (£18.92 million) in loan funding to Cell Therapy to execute a pivotal Phase 2b clinical study that could lead to the approval of its heart failure medicine CLXR-001 in the Gulf Cooperation Countries ("GCC") and 32.5% of the shares in Lumen to Cardiogeni and in return will receive 67.5% of the share capital. The drawdown of the second and third tranches of the Loan is subject only to the Phase 2b clinical trial for CLXR-001 continuing and to Cell Therapy's cash position. Drawdown will be phased as follows: $0.5 million (£0.3761925 million) on Completion, $10 million (£7.52385 million) by February 2027 and $10 million (£7.52385 million) by February 2028. The Loan will be funded by Kira and is expected to be supported by a written guarantee by Kira's principal investor. The loan carries 5% annual interest and the principle is to repaid in tranches starting on the December 31, 2028 subject to Cell Therapy generating profits from product sales or licensing fees. Following completion of the Transaction, Cardiogeni retains 32.5% of Cell Therapy. Following Completion, the Cardiogeni Board will be also become the Directors of Cell Therapy and Cardiogeni will retain effective control of Cell Therapy's finances and operations. Therefore, the Directors believe Cell Therapy will remain consolidated in the Cardiogeni's accounts. The terms and conditions of the service contracts of the Directors remain unchanged. Completion of the Transaction is conditional on verification of the Kira and Lumen's asset and cash positions. At Completion, the parties will also enter into a shareholders' agreement ("SHA") to govern the operation of Cell Therapy and the loan funding conditions and repayment schedule. Cardiogeni expects to receive a guarantee of the loan funding from Kira's principal investor. The Transaction is expected to complete no later than March 31, 2026. Brian Stockbridge of First Sentinel Corporate Finance Limited acted as financial advisor to Cardiogeni.お知らせ • Dec 09Cardiogeni PLC, Annual General Meeting, Dec 31, 2025Cardiogeni PLC, Annual General Meeting, Dec 31, 2025. Location: celixir house, innovation way, stratford upon avon, england, cv37 7gz, United KingdomNew Risk • Dec 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.68m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.68m market cap, or US$8.90m). Minor Risk Less than 3 years of financial data is available.Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.30m (US$8.18m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (UK£6.30m market cap, or US$8.18m).最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 17Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI).Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI) on March 16, 2026. In accordance with the terms of the proposed Transaction, Kira will provide up to $25 million (£18.92 million) in loan funding to Cell Therapy to execute a pivotal Phase 2b clinical study that could lead to the approval of its heart failure medicine CLXR-001 in the Gulf Cooperation Countries ("GCC") and 32.5% of the shares in Lumen to Cardiogeni and in return will receive 67.5% of the share capital. The drawdown of the second and third tranches of the Loan is subject only to the Phase 2b clinical trial for CLXR-001 continuing and to Cell Therapy's cash position. Drawdown will be phased as follows: $0.5 million (£0.3761925 million) on Completion, $10 million (£7.52385 million) by February 2027 and $10 million (£7.52385 million) by February 2028. The Loan will be funded by Kira and is expected to be supported by a written guarantee by Kira's principal investor. The loan carries 5% annual interest and the principle is to repaid in tranches starting on the December 31, 2028 subject to Cell Therapy generating profits from product sales or licensing fees. Following completion of the Transaction, Cardiogeni retains 32.5% of Cell Therapy. Following Completion, the Cardiogeni Board will be also become the Directors of Cell Therapy and Cardiogeni will retain effective control of Cell Therapy's finances and operations. Therefore, the Directors believe Cell Therapy will remain consolidated in the Cardiogeni's accounts. The terms and conditions of the service contracts of the Directors remain unchanged. Completion of the Transaction is conditional on verification of the Kira and Lumen's asset and cash positions. At Completion, the parties will also enter into a shareholders' agreement ("SHA") to govern the operation of Cell Therapy and the loan funding conditions and repayment schedule. Cardiogeni expects to receive a guarantee of the loan funding from Kira's principal investor. The Transaction is expected to complete no later than March 31, 2026. Brian Stockbridge of First Sentinel Corporate Finance Limited acted as financial advisor to Cardiogeni.お知らせ • Dec 09Cardiogeni PLC, Annual General Meeting, Dec 31, 2025Cardiogeni PLC, Annual General Meeting, Dec 31, 2025. Location: celixir house, innovation way, stratford upon avon, england, cv37 7gz, United KingdomNew Risk • Dec 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.68m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.68m market cap, or US$8.90m). Minor Risk Less than 3 years of financial data is available.Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.30m (US$8.18m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (UK£6.30m market cap, or US$8.18m).Board Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元CGNIGB BiotechsGB 市場7D0%-1.8%0.6%1Y-6.7%2.2%16.7%株主還元を見る業界別リターン: CGNI過去 1 年間で2.2 % の収益を上げたUK Biotechs業界を下回りました。リターン対市場: CGNIは、過去 1 年間で16.7 % のリターンを上げたUK市場を下回りました。価格変動Is CGNI's price volatile compared to industry and market?CGNI volatilityCGNI Average Weekly Movement0%Biotechs Industry Average Movement7.4%Market Average Movement5.1%10% most volatile stocks in GB Market10.5%10% least volatile stocks in GB Market2.7%安定した株価: データは利用できません。時間の経過による変動: 過去 1 年間のCGNIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20073Ajan Reginaldcardiogeni.com臨床段階のバイオテクノロジー企業であるCardiogeni PLCは、心不全治療薬の開発を行っている。同社の主力製品はCLXR-001で、冠動脈バイパス術中に投与する心不全患者治療用の特許取得済み人工細胞薬である。また、CLXR-002とCLXR-003を低侵襲で投与する心不全治療薬として、CLXR-004をLVADと組み合わせて使用する重症心不全治療薬として開発している。同社は2009年に設立され、英国ストラットフォード・アポン・エイボンに本社を置いている。もっと見るCardiogeni PLC 基礎のまとめCardiogeni の収益と売上を時価総額と比較するとどうか。CGNI 基礎統計学時価総額UK£6.73m収益（TTM）UK£1.10m売上高(TTM)UK£7.79m6.1xPER（株価収益率0.9xP/SレシオCGNI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CGNI 損益計算書（TTM）収益UK£7.79m売上原価UK£0売上総利益UK£7.79mその他の費用UK£6.70m収益UK£1.10m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）0.011グロス・マージン100.00%純利益率14.07%有利子負債／自己資本比率0%CGNI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/21 20:03終値2026/07/21 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cardiogeni PLC 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 17Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI).Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI) on March 16, 2026. In accordance with the terms of the proposed Transaction, Kira will provide up to $25 million (£18.92 million) in loan funding to Cell Therapy to execute a pivotal Phase 2b clinical study that could lead to the approval of its heart failure medicine CLXR-001 in the Gulf Cooperation Countries ("GCC") and 32.5% of the shares in Lumen to Cardiogeni and in return will receive 67.5% of the share capital. The drawdown of the second and third tranches of the Loan is subject only to the Phase 2b clinical trial for CLXR-001 continuing and to Cell Therapy's cash position. Drawdown will be phased as follows: $0.5 million (£0.3761925 million) on Completion, $10 million (£7.52385 million) by February 2027 and $10 million (£7.52385 million) by February 2028. The Loan will be funded by Kira and is expected to be supported by a written guarantee by Kira's principal investor. The loan carries 5% annual interest and the principle is to repaid in tranches starting on the December 31, 2028 subject to Cell Therapy generating profits from product sales or licensing fees. Following completion of the Transaction, Cardiogeni retains 32.5% of Cell Therapy. Following Completion, the Cardiogeni Board will be also become the Directors of Cell Therapy and Cardiogeni will retain effective control of Cell Therapy's finances and operations. Therefore, the Directors believe Cell Therapy will remain consolidated in the Cardiogeni's accounts. The terms and conditions of the service contracts of the Directors remain unchanged. Completion of the Transaction is conditional on verification of the Kira and Lumen's asset and cash positions. At Completion, the parties will also enter into a shareholders' agreement ("SHA") to govern the operation of Cell Therapy and the loan funding conditions and repayment schedule. Cardiogeni expects to receive a guarantee of the loan funding from Kira's principal investor. The Transaction is expected to complete no later than March 31, 2026. Brian Stockbridge of First Sentinel Corporate Finance Limited acted as financial advisor to Cardiogeni.
お知らせ • Dec 09Cardiogeni PLC, Annual General Meeting, Dec 31, 2025Cardiogeni PLC, Annual General Meeting, Dec 31, 2025. Location: celixir house, innovation way, stratford upon avon, england, cv37 7gz, United Kingdom
New Risk • Dec 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.68m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.68m market cap, or US$8.90m). Minor Risk Less than 3 years of financial data is available.
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.30m (US$8.18m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (UK£6.30m market cap, or US$8.18m).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 17Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI).Kira Health Invest AG signed a conditional share exchange agreement to acquire 67.50% stake in Cell Therapy Limited from Cardiogeni PLC (OFEX:CGNI) on March 16, 2026. In accordance with the terms of the proposed Transaction, Kira will provide up to $25 million (£18.92 million) in loan funding to Cell Therapy to execute a pivotal Phase 2b clinical study that could lead to the approval of its heart failure medicine CLXR-001 in the Gulf Cooperation Countries ("GCC") and 32.5% of the shares in Lumen to Cardiogeni and in return will receive 67.5% of the share capital. The drawdown of the second and third tranches of the Loan is subject only to the Phase 2b clinical trial for CLXR-001 continuing and to Cell Therapy's cash position. Drawdown will be phased as follows: $0.5 million (£0.3761925 million) on Completion, $10 million (£7.52385 million) by February 2027 and $10 million (£7.52385 million) by February 2028. The Loan will be funded by Kira and is expected to be supported by a written guarantee by Kira's principal investor. The loan carries 5% annual interest and the principle is to repaid in tranches starting on the December 31, 2028 subject to Cell Therapy generating profits from product sales or licensing fees. Following completion of the Transaction, Cardiogeni retains 32.5% of Cell Therapy. Following Completion, the Cardiogeni Board will be also become the Directors of Cell Therapy and Cardiogeni will retain effective control of Cell Therapy's finances and operations. Therefore, the Directors believe Cell Therapy will remain consolidated in the Cardiogeni's accounts. The terms and conditions of the service contracts of the Directors remain unchanged. Completion of the Transaction is conditional on verification of the Kira and Lumen's asset and cash positions. At Completion, the parties will also enter into a shareholders' agreement ("SHA") to govern the operation of Cell Therapy and the loan funding conditions and repayment schedule. Cardiogeni expects to receive a guarantee of the loan funding from Kira's principal investor. The Transaction is expected to complete no later than March 31, 2026. Brian Stockbridge of First Sentinel Corporate Finance Limited acted as financial advisor to Cardiogeni.
お知らせ • Dec 09Cardiogeni PLC, Annual General Meeting, Dec 31, 2025Cardiogeni PLC, Annual General Meeting, Dec 31, 2025. Location: celixir house, innovation way, stratford upon avon, england, cv37 7gz, United Kingdom
New Risk • Dec 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.68m (US$8.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.68m market cap, or US$8.90m). Minor Risk Less than 3 years of financial data is available.
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£6.30m (US$8.18m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (UK£6.30m market cap, or US$8.18m).
Board Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Jo Martin was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
